We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Expands Sprycel Label to Pediatric Ph+ CML

FDA Expands Sprycel Label to Pediatric Ph+ CML

FDA_Logo_Black_2016.gif
November 15, 2017

The FDA expanded the indication for Bristol-Myers Squibb’s Sprycel (dasatinib) to include the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. The approval was based on data from 97 pediatric patients with chronic-phase CML from two open-label trials in Phase I and Phase II.

After 24 months of treatment, 96.1 percent of newly diagnosed patients and 82.6 percent of patients resistant or intolerant to Gleevec (imatinib) had complete cytogenic response. With median follow-ups of more than 4.5 years, median durations of response could not be estimated, with more than half of responding patients not progressing at the time of data cut-off, according to the FDA.

The agency granted priority review and an orphan product designation to Sprycel for this indication. Sprycel was first approved in 2006 for adults with Ph+ CML or acute lymphoblastic leukemia resistant to prior therapy. In October 2010, Sprycel received accelerated approval for adults with newly diagnosed Ph+ CML in chronic phase.

View today's stories

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Bristol Myers Squibb logo

    UK’s NICE Rejects Opdivo and Yervoy Combo for Lung Cancer

  • ClearanceStamp_Orange.gif

    Medtronic Earns De Novo Clearance for AI Colonoscopy System

  • HealthCanada_Logo.gif

    Health Canada Introduces New Reporting Requirements to Reduce Shortages

  • Gilead_Logo.gif

    Gilead Halts Phase 3 Remdesivir Study in High-Risk Nonhospitalized COVID-19 Patients

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing